The Role of Natriuretic Peptides in Management of Premature Infants with Hemodynamically Significant Patent Arterial Duct
Evgenij G. Furman,
Aleksej N. Biyanov,
Artem Porodikov,
Oksana B. Bahmet’eva,
Vladimir G. Druzhen’kov https://doi.org/10.15690/vsp.v18i1.1987
Abstract
Hemodynamically significant patent arterial duct in premature infants can be the reason of life-threatening complications. Thus it is topical to define the high risk of such complications and mortality in early neonatal period. We have reviewed researches results covering prognostic value of natriuretic peptides level in premature infants with hemodynamically significant patent arterial duct. The data on management planning of such patients according to the A-type and B-type natriuretic peptides levels is presented.
About the Authors
Evgenij G. Furman
Wagner Perm State Medical University
Russian Federation
Perm’
Russian Federation
Perm’
Aleksej N. Biyanov
Wagner Perm State Medical University;
Sukhanov Federal Center of Cardiovascular Surgery
Russian Federation
Perm’
Russian Federation
Perm’
Artem Porodikov
Sukhanov Federal Center of Cardiovascular Surgery
Russian Federation
Perm’
Russian Federation
Perm’
Oksana B. Bahmet’eva
Perm Regional Clinical Hospital
Russian Federation
Perm’
Russian Federation
Perm’
Vladimir G. Druzhen’kov
Perm Regional Clinical Hospital
Russian Federation
Perm’
Russian Federation
Perm’
References
1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a syste matic analysis and implications. Lancet. 2012;379(9832):2162–272. doi: 10.1016/S0140-6736(12)60820-4.
2. Ivanova IE. Physical development of premature infants (Lecture). Zdravoohranenie Chuvashii. 2014;(1):52–60. (In Russ).
3. Valiulina AYa, Ahmadeeva EN, Kryivkina NN. The problems and perspectives of successful resuscitation and rehabilitation children born with low and extremely low birth weight. Vestnik sovremennoy klinicheskoy meditsinyi. 2013;6(1):34–41. (In Russ).
4. Prahov AV, Gaponenko VA, Ignashina EG. Bolezni serdtsa ploda i novorozhdennogo rebenka. Seriya «Neonatal’naya kardiologiya». N. Novgorod: Izd-vo Nizhegorodskoy gos. med. Akademii; 2001. 188 р. (In Russ).
5. Volyanyuk EV. Gemodinamicheski znachimyiy otkryityiy arterialnyiy protok u nedonoshennyih novorozhdennyih. Prakticheskaya meditsina. 2010;(5):73–75. (In Russ).
6. Kryuchko DS, Baybarina EN, Rudakova AA. Open arterial duct in premature newborn: tactics of neonatologist. Voprosy sovremennoi pediatrii — Current Pediatrics. 2011;10(1):58–65. (In Russ).
7. Sehgal A, McNamara PJ. International perspective on management of a patent ductus arteriosus: Lessons learned. Semin Fetal Neonatal Med. 2018;23(4):278–284. doi: 10.1016/j.siny. 2018.03.002.
8. Protokol vedeniya nedonoshennyih detey s gemodinamicheski znachimyim funktsioniruyuschim arterialnyim protokom. Metodicheskie rekomendatsii. Ed by Volodin NN, Baybarina EN. Moscow; 2009. 34 р. (In Russ).
9. Vinogradova IV, Krasnov MV, Ivanova NN. Condition peculiarities of cardio-vascular system of newborns with very low birth weight. Meditsinskiy almanah. 2009;(4):103–106. (In Russ).
10. El-Khuffash A, Barry D, Walsh K, et al. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal. 2008;93(6):F407–412. doi: 10.1136/adc.2007.133140.
11. Lee JH, Ro SK, Lee HJ, et al. surgical ligation on significant patent ductus arteriosus in very low birth weight infants: comparison between early and late ligations Korean J Thorac Cardiovasc Surg. 2014;47(5):444–450. doi: 10.5090/kjtcs.2014.47.5.444.
12. Puddy VF, Amirmansour C, Williams AF, et al. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002;103(1):75–77. doi: 10.1042/cs1030075.
13. Kim JS, Shim EJ. B-type natriuretic peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J. 2012;42(3):192–196. doi: 10.4070/kcj.2012.42.3.192.
14. Ramakrishnan S, Heung YM, Round J, et al. Early N-ter minal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Acta Paediatr. 2009;98(8):1254–1259. doi: 10.1111/j.1651-2227.2009.01315.x.
15. El-Khuffash A, Amoruso M, Culliton M, Molloy EJ. N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study. Arch Dis Child Fetal Neonatal Ed. 2007;92(5):F421–422. doi: 10.1136/adc.2007.119701.
16. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92(5):628–631. doi: 10.1016/s0002-9149(03)00741-0.
17. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2008;93(4): F257–260. doi: 10.1136/adc.2007.120691.
18. Takeishi Y. Biomarkers in heart failure. Int Heart J. 2014; 55(6):474–481. doi: 10.1536/ihj.14-267.
19. El-Khuffash A, Molloy E. The use of n-terminal-pro-bnp in preterm infants. Int J Pediatr. 2009;2009:175216. doi: 10.1155/2009/175216.
20. Weisz DE, McNamara PJ, El-Khuffash A. Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. Early Hum Dev. 2017;105:41–47. doi: 10.1016/j.earlhumdev.2016.12.007.
21. Kozlova IA, Kharlamova IY. Natriuretic peptides: biochemistry, physiology, clinical implication. General Reanimatology. 2009;V(1):89–97. (In Russ). doi: 10.15360/1813-9779-2009-1-89.
22. Chen S, Tacy T, Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol. 2010;30(12):780–785. doi: 10.1038/jp.2010.47.
23. Czernik C, Lemmer J, Metze B, et al. B-type natriuretic peptide to predict ductus intervention in infants ˂ 28 weeks. Pediatr Res. 2008;64(3):286–290. doi: 10.1203/PDR.0b013e3181799594.
24. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004; 6(3):261–268. doi: 10.1016/j.ejheart.2004.01.004.
25. Bar-Oz B, Lev-Sagie A, Arad I, et al. N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. Clin Chem. 2005;51(5):926–927. doi: 10.1373/clinchem.2005.048892.
26. Jeong HA, Shin J, Kim E, et al. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. Korean J Pediatr. 2016;59(4): 183–189. doi: 10.3345/kjp.2016.59.4.183.
27. Noori S, Seri I. Pathophysiology of newborn hypotension outside the transitional period. Early Hum Dev. 2005;81(5):399–404. doi: 10.1016/j.earlhumdev.2005.03.007.
28. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart. 2003;89(8):875–878. doi: 10.1136/heart.89.8.875.
29. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr. 2001;90(2):184–191. doi: 10.1111/j.1651-2227.2001.tb00282.x.
30. Hammerman C, Shchors I, Schimmel MS, et al. N-terminal-proB-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool? Pediatr Cardiol. 2010;31(1):62–65. doi: 10.1007/s00246-009-9568-1.
31. Buddhe S, Dhuper S, Kim R, et al. NT-proBNP levels improve the ability of predicting a hemodynamically significant patent ductus arteriosus in very low-birth-weight infants. J Clin Neonatol. 2012;1(2):82–86. doi: 10.4103/2249-4847.96758.
32. Letshwiti JB, Sirc J, O’Kelly R, Miletin J. Serial N-terminal probrain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life. J Pediatr. 2014; 173(11):1491–1496. doi: 10.1007/s00431-014-2350-2.
33. Nir A, Lindinger A, Rauh M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol. 2009;30(1):3–8. doi: 10.1007/s00246-008-9258-4.
34. El-Khuffash A, Higgins M, Walsh K, Molloy EJ. Quantitative assessment of the degree of ductal steal using celiac artery blood flow to left ventricular output ratio in preterm infants. Neonatology. 2008;93(3):206–212. doi: 10.1159/000110869.
35. Bhat R, Das UG. Management of patent ductus arteriosus in premature infants. Indian J Pediatr. 2015;82(1):53–60. doi: 10.1007/s12098-014-1646-6.
36. Gournay V. Complications of cyclooxygenase inhibition in preterm infants. In: Obladen M, Koehne P. (eds) Interventions for persisting ductus arteriosus in the preterm infant. Springer, Berlin, Heidelberg; 2005. рр. 74–83. doi: 10.1007/3-540-26509-0_15.
37. Sung SI, Chang YS, Chun JY, et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr. 2016;177:66–71.e1. doi: 10.1016/j.jpeds.2016.06.046.
38. Barikbin P, Sallmon H, Wilitzki S, et al. Lung function in very low birth weight infants after pharmacological and surgical treatment of patent ductus arteriosus — a retrospective analysis. BMC Pediatr. 2017;17(1):5. doi: 10.1186/s12887-016-0762-z.
39. Noori S. Pros and cons of patent ductus arteriosus ligation: hemodynamic changes and other morbidities after patent ductus arteriosus ligation. Semin Perinatol. 2012;36(2):139–145. doi: 10.1053/j.semperi.2011.09.024.
40. Avsar MK, Demir T, Celiksular C, Zeybek C. Bedside PDA ligation in premature infants less than 28 weeks and 1000 grams. J Cardiothorac Surg. 2016;11(1):146. doi: 10.1186/s13019-016-0539-3.
41. Fonseca E, Georgiev SG, Gorenflo M, Loukanov TS. Patent ductus arteriosus in preterm infants: Benefits of early surgical closure. Asian Cardiovasc Thorac Ann. 2014;22(4):391–396. doi: 10.1177/0218492313480051.
42. Biyanov AN, Porodikov AA. Hemodynamically significant functioning arterial duct in newborns with extremely low and very low body weight: a modern view on the surgical treatment. Pediatriya. 2018;97(5):141–145. (In Russ). doi: 10.24110/0031-403X2018-97-5-141-145.
43. Hsu JH, Yang SN, Chen HL, et al. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr. 2010;157(1):79–84. doi: 10.1016/j.jpeds.2009.12.045.
44. Mine K, Ohashi A, Tsuji S, et al. B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. Acta Paediatr. 2013;102(8): e347–352. doi: 10.1111/apa.12273.
45. Montaner Ramon A, Galve Pradel Z, Fernandez Espuelas C, et al. Usefulness of brain natriuretic propeptide in the diagnosis and management of patent ductus arteriosus [Article in Spanish]. An Pediatr (Barc). 2017;86(6):321–328. doi: 10.1016/j.anpedi.2016.01.007.
46. Kulkarni M, Gokulakrishnan G, Price J, et al. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics. 2015;135(2):e510–525. doi: 10.1542/peds.2014-1995.
Review
For citations:
Furman E.G., Biyanov A.N., Porodikov A., Bahmet’eva O.B., Druzhen’kov V.G. The Role of Natriuretic Peptides in Management of Premature Infants with Hemodynamically Significant Patent Arterial Duct. Current Pediatrics. 2019;18(1):8-12. (In Russ.) https://doi.org/10.15690/vsp.v18i1.1987
Views:
1421
Email this article 
